Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors

Abstract

A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: W is O, N—H, N—(C-Calkyl) or S; each X is independently CH or N; Ris a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O; Ris LY; each L is a direct bond, C-Calkylene, C-Calkenylene or C-Calkynylene; Y is an optionally substituted fused, bridged or spirocyclic non-aromatic 5-12 membered heterocycle containing up to 4 heteroatoms selected from N or O; and each Ris independently H, C-Calkyl, halogen, fluoro C-Calkyl, O—C-Calkyl, NH—C-Calkyl, S—C-Calkyl, O-fluoro C-Calkyl, NH-acyl, NH—C(O)—NH—C-Calkyl, C(O)—NH—C-Calkyl, aryl or heteroaryl, are useful as inhibitors of the class IA phosphoinositide 3-kinase enzyme, PI3K-p110δ, and therefore have potential utility in the therapy of cancer, immune and inflammatory diseases.